Stocks · News reference
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from
Read original at benzingaFiled: 2026-08-13 AccNo: 0001759138-26-000038 Size: 322 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar